Redirecting to https://www.businesswire.com/news/home/20250531731865/en/Avistone-Announces-Encouraging-Results-for-Vebreltinib-plus-Andamertinib-PLB1004-in-EGFR-mutated-NSCLC-with-MET-Amplification-or-Overexpression-at-ASCO-Annual-Meeting-2025